Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Sarkis K. Mazmanian | M | - |
Symbiotix Biotherapies, Inc.
 Symbiotix Biotherapies, Inc. BiotechnologyHealth Technology Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA. | 15 anni |
| Peter Alff | M | - |
Symbiotix Biotherapies, Inc.
Symbiotix Biotherapies, Inc. BiotechnologyHealth Technology Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA. | - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Nader Yaghoubi | M | - |
Symbiotix Biotherapies, Inc.
Symbiotix Biotherapies, Inc. BiotechnologyHealth Technology Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA. | - |
| Sheila Mikhail | F | 57 |
Symbiotix Biotherapies, Inc.
Symbiotix Biotherapies, Inc. BiotechnologyHealth Technology Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA. | - |
| Lloyd Kasper | M | - |
Symbiotix Biotherapies, Inc.
Symbiotix Biotherapies, Inc. BiotechnologyHealth Technology Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA. | - |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Stati Uniti | 5 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Dennis Kasper
- Contatti personali
